Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.

Current oncology (Toronto, Ont.) - 16 Sept 2022

Jóri Balázs, Falk Markus, Hövel Iris, Weist Peggy, Tiemann Markus, Heukamp Lukas C, Griesinger Frank

Abstract excerpt

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK+ patients. However, lorlatinib-induced resistance mechanisms, and its efficacy against the resistance mutation G2032R in ROS1, respectively, have not yet been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lactams

Share to Lactams, Macrocyclic

Share to Liquid Biopsy

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 36135089
DOI: 10.3390/curroncol29090520
PMCID: PMC9497554

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.PMID 36135089Read ↗

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Semantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

BRAF p.V600E Mutation as Acquired Resistance Mechanism of Lorlatinib in a ROS1 Rearrangement Lung Adenocarcinoma Patient with Primary Ceritinib ResistanceSemantic proximity Read ↗

Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study.Semantic proximity Read ↗

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current PerspectivesSemantic proximity Read ↗

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsSemantic proximity Read ↗

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.Semantic proximity Read ↗

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant AlterationsSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.